Form 4: Agilon Health Director Silvana Battaglia Receives Significant RSU Grant

Agilon Health, Inc. Director Silvana Battaglia was granted 78,724 restricted stock units (RSUs) on May 28, 2025, aligning her interests with shareholders.

Summary

• Silvana Battaglia, a Director of agilon health, inc. (AGL), acquired 78,724 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction occurred on May 28, 2025, with an acquisition price of $0 per unit, typical for RSU grants.
• Following this transaction, Ms. Battaglia beneficially owns a total of 144,868 shares, which includes these newly acquired RSUs.
• The newly granted RSUs are scheduled to vest in full on May 28, 2026, contingent upon her continued service as a director.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a director receiving an equity grant typically signals alignment of interests and confidence in the company's future, without any negative implications from the filing itself.

Positives

• The grant of Restricted Stock Units to a director aligns management and board interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects.

Risks

• The value of the restricted stock units is subject to market fluctuations of agilon health, inc.'s common stock.
• The RSUs are subject to forfeiture if the director's service to the company ceases before the vesting date of May 28, 2026.

Future Outlook

The future outlook for the granted RSUs is tied to the company's stock performance and the director's continued service until the vesting date of May 28, 2026.

Industry Context

The granting of Restricted Stock Units (RSUs) is a common form of equity compensation for directors and executives in the healthcare services industry, including value-based care providers like agilon health. This practice aims to incentivize long-term performance and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across various industries, including healthcare, aligning with corporate governance best practices aimed at fostering long-term value creation.
• While the specific number of units granted (78,724) would typically be benchmarked against peer companies of similar market capitalization and industry sector (e.g., Oak Street Health, Privia Health Group, Cano Health) to assess competitiveness and appropriateness, this filing alone does not provide sufficient context for a detailed comparative analysis of compensation levels.

Related Party Transactions

• The acquisition of 78,724 Restricted Stock Units by Silvana Battaglia, a Director of agilon health, inc., represents a compensation transaction between the company and a related party.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with those of shareholders, as the value of the compensation is directly tied to the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The Restricted Stock Units are expected to vest on May 28, 2026, subject to Silvana Battaglia's continued service as a director.

Key Dates

Keywords

agilon health, AGL, SEC Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership